Department of Basic Medical Sciences, Faculty of Medicine, Yarmouk University, Irbid, Jordan.
Department of Biological Sciences, Faculty of Science, Yarmouk University, Irbid, Jordan.
PLoS One. 2024 Jun 12;19(6):e0305431. doi: 10.1371/journal.pone.0305431. eCollection 2024.
The incidence of antimicrobial resistance is alarmingly high because it occurs in humans, environment, and animal sectors from a "One Health" viewpoint. The emergence of plasmid-carried mobile colistin-resistance (MCR) genes limits the efficacy of colistin, which is the last-line treatment for multidrug resistance (MDR) against gram-negative infections.
The current study aimed to investigate emergence of colistin-resistance (MCR 1-5) genes in E. coli isolated from patients with urinary tract infections (UTIs) in Jordan.
E. coli (n = 132) were collected from urine specimens. The E. coli isolated from human UTI patients were examined the resistance to colistin based on the presence of MCR (1-5). All isolates were tested against 20 antimicrobials using the standard disk diffusion method. The broth microdilution technique was used to analyze colistin resistance. In addition, the MCR (1-5) genes were detected using multiplex PCR.
Out of the 132 isolates, 1 isolate was colistin-resistant, having a minimum inhibitory concentration of 8 μg/mL and possessing MCR-1. All the E. coli isolates showed high resistance to penicillin (100%), amoxicillin (79.55%), cephalexin (75.76%), nalidixic acid (62.88%), tetracycline (58.33%), or cefepime (53.79).
To our knowledge, this is the first report on the presence of plasmid-coded MCR-1 in E. coli from a patient with UTIs in Jordan. This is a problematic finding because colistin is the last-line drug for the treatment of infections caused by MDR gram-negative bacteria. There is a crucial need to robustly utilize antibiotics to control and prevent the emergence and prevalence of colistin-resistance genes.
从“同一健康”的角度来看，由于人类、环境和动物领域都存在抗生素耐药性，因此抗生素耐药性的发生率令人震惊。质粒携带的移动多粘菌素耐药（MCR）基因的出现限制了多粘菌素的疗效，多粘菌素是治疗革兰氏阴性感染的多药耐药（MDR）的最后一线药物。
本研究旨在调查 MCR 1-5 基因在从约旦尿路感染（UTI）患者中分离的大肠杆菌中的出现情况。
从尿液标本中收集大肠杆菌（n=132）。根据 MCR（1-5）的存在，检查从人 UTI 患者中分离的大肠杆菌对多粘菌素的耐药性。所有分离株均采用标准纸片扩散法检测 20 种抗生素的耐药性。采用肉汤微量稀释法分析多粘菌素耐药性。此外，使用多重 PCR 检测 MCR（1-5）基因。
在 132 株分离株中，有 1 株对多粘菌素耐药，最低抑菌浓度为 8 μg/ml，且携带 MCR-1。所有大肠杆菌分离株对青霉素（100%）、阿莫西林（79.55%）、头孢氨苄（75.76%）、萘啶酸（62.88%）、四环素（58.33%）或头孢吡肟（53.79%）均表现出高度耐药性。
据我们所知，这是约旦首例尿路感染患者产质粒编码 MCR-1 的大肠杆菌报告。这是一个有问题的发现，因为多粘菌素是治疗 MDR 革兰氏阴性菌引起的感染的最后一线药物。迫切需要强有力地利用抗生素来控制和预防多粘菌素耐药基因的出现和流行。
